Dawson James Securities launched coverage of Dyadic International (NASDAQ:DYAI) with a “buy” rating and $14 price target. The stock closed at $6.66 on Oct. 15. Dyadic has been developing a gene expression platform over...
Kane Biotech (TSXV:KNE) and Dechra Veterinary Products, a unit of Dechra Pharmaceuticals (LSE:DPH), expanded their 10-year exclusive license and distribution agreement to include South America. The agreement was...
Stifel launched coverage of IGM Biosciences (NASDAQ:IGMS) with a “buy” rating and $32 price target. The stock closed at $17.25 on Oct. 11. “We believe the company’s first/only-in-class, IgM-based antibody platform...
Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). IMU-838 is a selective immune modulator that blocks the enzyme...
In addition to receiving FDA fast track designation for FX-322, Frequency Therapeutics (NASDAQ:FREQ) initiated dosing in a Phase 2a clinical study of the drug candidate for the treatment of sensorineural hearing loss...
BrainStorm Cell Therapeutics (NASDAQ:BCLI) completed enrollment of its 200-patient Phase 3 trial evaluating NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). The NurOwn process involves isolating...
Geron (NASDAQ:GERN) dosed the first patient in its Phase 3 clinical trial evaluating imetelstat, a telomerase inhibitor, in lower risk myelodysplastic syndromes (MDSs). MDSs occur when bone marrow cells do not mature...
Profound Medical (TSX:PRN; OTCQX:PRFMF) implemented a one-for-10 consolidation of its shares outstanding to qualify for a potential listing on The NASDAQ Stock Market. Shareholders approved the consolidation at the...
William Blair initiated coverage of Exagen (NASDAQ:XGN) with an “outperform” rating based on an outlook for business trends, potential upside to revenue estimates, and its relative valuation to comparable diagnostic...
Stephen Harrison Hepion Pharmaceuticals (NASDAQ:HEPA) appointed world-renowned Dr. Stephen Harrison as consultant medical director. Dr. Harrison is a peer-reviewer for more than 20 medical journals. He is...
H.C. Wainwright launched coverage of Aravive (NASDAQ:ARAV) with a “buy” rating and $18 price target. The stock closed at $6.38 on Oct. 9. The company’s lead asset is AVB-500, an anti-GAS6 selective decoy, used to...
Ian Frazer Anixa Biosciences (NASDAQ:ANIX) appointed cancer vaccine pioneer, Dr. Ian Frazer, to its scientific advisory board. Dr. Frazer is a leading immunologist recognized as one of the first scientists to...